Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.62 |
| ▸ | MMP2 | P08253 | 1/20 | 0.57 |
| ▸ | MMP7 | P09237 | 1/20 | 0.57 |
| ▸ | MMP9 | P14780 | 1/20 | 0.57 |
| ▸ | MMP12 | P39900 | 1/20 | 0.57 |
| ▸ | MMP13 | P45452 | 1/20 | 0.57 |
| ▸ | MMP1 | P03956 | 1/20 | 0.56 |
| ▸ | FCER2 | P06734 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6447264 | 1.00 | MME (0.62) | MMEMMP2MMP7MMP9MMP12 | |
| SCHEMBL6447498 | 1.00 | MME (0.62) | MMEMMP2MMP7MMP9MMP12 | |
| SCHEMBL6447730 | 0.92 | MME (0.66) | MMEMMP1FCER2LTA4H | |
| SCHEMBL6447736 | 0.92 | MME (0.66) | MMEMMP1FCER2LTA4H | |
| SCHEMBL6447734 | 0.92 | MME (0.66) | MMEMMP1FCER2LTA4H | |
| SCHEMBL6447062 | 0.88 | MME (0.54) | MMEMMP2MMP1LTA4H | |
| SCHEMBL6447064 | 0.88 | MME (0.54) | MMEMMP2MMP1LTA4H | |
| SCHEMBL6447060 | 0.88 | MME (0.54) | MMEMMP2MMP1LTA4H | |
| SCHEMBL9727512 | 0.85 | MME (0.47) | MMEMMP2MMP7MMP9MMP12 | |
| SCHEMBL9222947 | 0.82 | CPA1 (0.71) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | MME 11/4885MMP2 45/4885MMP7 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.